Mind the gaps - The epidemiology of poor-quality anti-malarials in the malarious world - Analysis of the WorldWide Antimalarial Resistance Network database

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Tabernero, Patricia ^a,b,c   Fernández, Facundo M ^d   Green, Michael ^e   Guerin, Philippe J ^a,b   Newton, Paul N ^a,b,c,f  

^a WorldWide Antimalarial Resistance Network   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAHOSOT HOSPITAL   (Laos)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; ARTESUNATE; ATOVAQUONE; CHLOROQUINE; CLINDAMYCIN; CYCLOGUANIL; DAPSONE PLUS PYRIMETHAMINE; MERCAPTOBENZOTHIAZOLE; PARACETAMOL; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

ANTIMALARIAL QUALITY SURVEY; ARTICLE; CHEMICAL ANALYSIS; COLORIMETRY; DISSOLUTION; DRUG PACKAGING; DRUG QUALITY; HEALTH SURVEY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALARIA; MASS SPECTROMETRY; PHARMACOEPIDEMIOLOGY; PUBLICATION; QUALITY CONTROL; SYSTEMATIC REVIEW (TOPIC); THIN LAYER CHROMATOGRAPHY;

ANTIMALARIALS; COUNTERFEIT DRUGS; DATABASES, PHARMACEUTICAL; DRUG PACKAGING; HUMANS; MALARIA;

EID: 84899494126     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-139     Document Type: Article

References (71)

1. World Health Organization, World Malaria Report 2012 2012 [cited 2013 March, 17th]; Available from: http://www.who.int/malaria/publications/world- malaria-report-2012/en/
2. United Nations Human Rights Council, Access to medicines in the context of the right of everyone to the to the enjoyment of the highest attainable standard of physical and mental health Twenty-third session, Agenda item 3, Promotion and protection of all human rights, civil, political, economic, social and cultural rights, including the right to development 2013 [cited 2013 June 20th]; Available from: http://ap.ohchr.org/documents/dpage-e.aspx?si=A/HRC/23/L. 10/rev.1
3. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Médicaments sous-standard dans les milieux défavorisés: un problème qui ne peut plus être ignoré. Revue Medicamentos sub-estándar en lugares con pocos recursos: un problema que no puede ser ignorado por más tiempo. Revisión. Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J, Tropical Med Int Health 2008 13 8 1062 1072 10.1111/j.1365-3156.2008. 02106.x
4. Institute of Medicine of the National Academies, Countering the Problem of Falsified and Substandard Drugs National Academy of Sciences. The National Academies Press 2013 Available from: http://www.iom.edu/reports/2013/countering- the-problem-of-falsified-and-substandard-drugs.aspx
5. Poor quality vital antimalarials in Africa-an urgent neglected public health priority. Newton PN, Green MD, Mildenhall DC, Plancon A, Nettey H, Nyadong L, Hostetler DM, Swamidoss I, Harris GA, Powell K, Timmermans AE, Amin AA, Opuni SK, Barbereau S, Faurant C, Soong RCW, Faure K, Thevanayagam J, Fernandes P, Kaur H, Angus B, Stepniewska K, Guerin PJ, Fernandez FM, Malar J 2011 10 352 10.1186/1475-2875-10-352 22152094
6. A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal. Dorlo TPC, Eggelte TA, Schoone GJ, de Vries PJ, Beijnen JH, PLoS Negl Trop Dis 2012 6 5 1544 10.1371/journal.pntd.0001544 22666507
7. Pakistan's deadly cocktail of substandard drugs. Nishtar S, Lancet 2012 379 9821 1084 5 10.1016/S0140-6736(12)60277-3 22394558
8. Food & Agricultural Organisation of the United Nations (FAO), Report on the investigation of the quality of diminazene preparations in sub-Saharan Africa in Report prepared under a Special Services Agreement to investigate the quality of veterinary trypanocides in sub-Saharan Africa Food & Agricultural Organisation of the United Nations, Tettey JNA, 2001
9. The WWARN Antimalarial Quality Surveyor. Tabernero P, Newton PN, Pathog Glob Health 2012 106 2 77 78 10.1179/204777312X13419245939520 22943540
10. U.S. Food & Drug Administration (FDA), Counterfeit Version of Avastin in U.S. Distribution 2012 [cited 2012 February, 14]; Available from: http://www.fda.gov/Drugs/DrugSafety/ucm291960.htm
11. Counterfeit anti-infective drugs. Newton PN, Green MD, Fernandez FM, Day NP, White NJ, Lancet Infect Dis 2006 6 602 613 10.1016/S1473-3099(06)70581-3 16931411
12. Saunders W, Observations on the superior efficacy of the Red Peruvian Bark London, UK: J Johnson & J Murray Letter from Dr Edward Rigby, Norwich, 8th September 1782. Vol. 4th edition. 1782
13. America's First Drug Regulation Regime: The Rise and Fall of the Import Drug Act of 1848. Heath WJ, Food Drug Law J 2004 59 169 200 15212037
14. Drug Adulteration. GP A, Lancet 1826 6 147 413
15. Adulteration Quinine. Croft CJ, Lancet 1838 31 794 292 10.1016/S0140-6736(02)82655-1
16. How to achieve international action on falsified and substandard medicines. Attaran A, Barry D, Basheer S, Bate R, Benton D, Chauvin J, Garrett L, Kickbusch I, Kohler JC, Midha K, Newton PN, Nishtar S, Orhii P, Martin McKee M, BMJ 2012 345
17. The Primacy of Public Health Considerations in Defining Poor Quality Medicines. Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, Simons B, Bate R, Guerin PJ, White NJ, PLoS Med 2011 8 12 1001139 10.1371/journal.pmed. 1001139 22162953
18. European Union, Amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products., in Directive 2011/62/EU Of The European Parliament And Of The Council Official Journal of the European Union 2011 74 87 Available from: http://ec.europa.eu/health/files/ eudralex/vol-1/dir-2011-62/dir-2011-62-en.pdf
19. A counterfeit drug treaty: Great idea, wrong implementation. Bate R, Attaran A, Lancet 2010 376 9751 1446 1448 10.1016/S0140-6736(10)61416-X 21036261
20. WHO, Substandard/spurious/falsely-labelled/falsified/counterfeit medical products: report of the Working Group of Member States. Sixty-fifth World Health Assembly. Provisional Agenda item 13.13 A65/23 WHO 2012 Available from: http://apps.who.int/gb/ebwha/pdf-files/WHA65/A65-23-en.pdf
21. Fast detection and identification of counterfeit antimalarial tablets by Raman spectroscopy. de Veij M, Vandenabeele P, Hall KA, Fernandez FM, Green MD, White NJ, Dondorp AM, Newton PN, Moens L, J Raman Spectrosc 2007 38 2 181 187 10.1002/jrs.1621
22. Assessment of hand-held Raman instrumentation for in situ screening for potentially counterfeit artesunate antimalarial tablets by FT-Raman spectroscopy and direct ionization mass spectrometry. Ricci C, Nyadong L, Yang F, Fernandez FM, Brown CD, Newton PN, Kazarian SG, Anal Chim Acta 2008 623 2 178 186 10.1016/j.aca.2008.06.007 18620922
23. Characterization of genuine and fake artesunate anti-malarial tablets using Fourier transform infrared imaging and spatially offset Raman spectroscopy through blister packs. Ricci C, Eliasson C, Macleod N, Newton P, Matousek P, Kazarian S, Anal Bioanal Chem 2007 389 5 1525 1532 10.1007/s00216-007-1543-1 17879090
24. Characterization of Solid Counterfeit Drug Samples by Desorption Electrospray Ionization and Direct-analysis-in-real-time Coupled to Time-of-flight Mass Spectrometry. Fernández FM, Cody RB, Green MD, Hampton CY, McGready R, Sengaloundeth S, White NJ, Newton PN, ChemMedChem 2006 1 7 702 705 10.1002/cmdc.200600041 16902921
25. Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries. Fernandez FM, Hostetler D, Powell K, Kaur H, Green MD, Mildenhall DC, Newton PN, R Soc of Chem 2010 136 15 3073 3082
26. Antimalarial drug quality: Methods to detect suspect drugs. Kaur H, Green MD, Hostetler DM, Fernandez FM, Newton PN, Therapy 2010 7 1 49 57 10.2217/thy.09.84
27. Artemisinin Resistance in Plasmodium falciparum Malaria. Dondorp AM, Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 5 455 467 10.1056/NEJMoa0808859 19641202
28. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. White N, Pongtavornpinyo W, Maude R, Saralamba S, Aguas R, Stepniewska K, Lee S, Dondorp A, White L, Day N, Malar J 2009 8 1 253 10.1186/1475-2875-8-253 19906307
29. Guidelines for field surveys of the quality of medicines: A proposal. Newton PN, Lee SJ, Goodman C, Fernandez FM, Yeung S, Phanouvong S, Kaur H, Amin AA, Whitty CJM, Kokwaro GO, Lindegardh N, Lukulay P, White LJ, Day NPJ, Green MD, White NJ, PLoS Med 2009 6 3 0252 0257
30. Worldwide Antimalarial Resistance Network, A.Q.S.G, Antimalarial Quality Surveyor 2012 [cited 2013 December 12th]; Available from: http://www.wwarn.org/ resistance/surveyors/antimalarial-quality
31. Worldwide Antimalarial Resistance Network, A.Q.S.G, Antimalarial Quality Surveyor. Methodology 2012 [cited 2013 December 16th]; Available from: http://www.wwarn.org/resistance/surveyors/antimalarial-quality/methodology
32. Impaired Clinical Response in a Patient with Uncomplicated Falciparum Malaria Who Received Poor-Quality and Underdosed Intramuscular Artemether. Keoluangkhot V, Green MD, Nyadong L, Fernández FM, Mayxay M, Newton PN, AmJTrop Med Hyg 2008 78 4 552 555
33. A Nationwide Survey of the Quality of Antimalarials in Retail Outlets in Tanzania. Kaur H, Goodman C, Thompson E, Thompson K-A, Masanja I, Kachur SP, Abdulla S, PLoS One 2008 3 10 3403 10.1371/journal.pone.0003403 18923672
34. Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, Okoye V, Okonkwo P, Malar J 2009 8 1 22 10.1186/1475-2875-8-22 19208221
35. Quality of oral and parenteral chloroquine in Kampala. Ogwal-Okeng JW, Okello DO, Odyek O, East Afr Med J 1998 75 12 692 694 10065207
36. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, Wangboonskul J, Reid RG, Kolawole JA, Lancet 2001 357 9272 1933 1936 10.1016/S0140-6736(00)05065-0 11425415
37. Comparative analysis of eight brands of sulfadoxinepyrimethamine tablets. Odeniyi MA, Trop J Pharm Res 2003 2 1 161 167
38. A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR-implications for therapeutic failure and drug resistance. Sengaloundeth S, Green MD, Fernandez FM, Manolin O, Phommavong K, Insixiengmay V, Hampton CY, Nyadong L, Mildenhall DC, Hostetler D, Khounsaknalath L, Vongsack L, Phompida S, Vanisaveth V, Syhakhang L, Newton PN, Malar J 2009 8 172 10.1186/1475-2875-8-172 19638225
39. IPR in China, Judicial Protection of IPR in China. GlaxoSmithKline Case Study Intellectual Property Rights in China 2000 December 2000 [cited March 3rd, 2013]; Available from: http://www.chinaiprlaw.com/english/news/news14.htm
40. Manslaughter by Fake Artesunate in Asia-Will Africa Be Next? Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Whitty CJM, Talisuna AO, Proux S, Christophel EM, Malenga G, Singhasivanon P, Bojang K, Kaur H, Palmer K, Day NPJ, Greenwood BM, Nosten F, White NJ, PLoS Med 2006 3 6 197 10.1371/journal.pmed.0030197 16752952
41. Ndomondo-Sigonda M, Counteracting Counterfeiting: Strategies for Improving the Integrity of the Medicinal Marketplace in Tanzania Tanzania Food and Drugs Authority 2005 Available from: http://projects.msh.org/seam/reports/ fip-cairo-2005/57-counteracting.pdf
42. News MG, Pharmacia Withdraws Metakelfin in White Sachets modern.ghana.com 2002 [cited 2011 November, 7th]; Available from: http://www.modernghana.com/ news/20469/1/pharmacia-withdraws-metakelfin-in-white-sachets.html
43. Fake drugs- A new threat to health-care delivery. Sesay MM, Africa Health 1988
44. Medicines informal market in Congo, Burundi and Angola: counterfeit and sub-standard antimalarials. Gaudiano M, Di Maggio A, Cocchieri E, Antoniella E, Bertocchi P, Alimonti S, Valvo L, Malar J 2007 6 1 22 10.1186/1475-2875-6-22 17316432
45. Molecular Epidemiology of Malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Basco LK, AmJTrop Med Hyg 2004 70 3 245 250
46. Mugabe D, Fake drugs hit Ugandan market 2009 [cited 2012 October 8th]
47. Drug Regulation and Control in Nigeria: The Challenge of Counterfeit Drugs. Erhun WO, Babalola OO, Erhun MO, J Health Popul Dev Ctries 2001 4 2 23 24
48. Analysis of counterfeit antimalarial drugs. Alter K, Fernández F, Green M, Newton PN, Eur Pharm Rev 2004 2004 3
49. Characterization of Counterfeit Artesunate antimalarial tablets from Southeast Asia. Hall KA, Newton PN, Green MD, De Veij M, Vandenabeele P, Pizzanelli D, Mayxay M, Dondorp A, Fernández FM, AmJTrop Med Hyg 2006 75 5 804 811
50. Bagala A, 3 held over fake malaria drugs 2008 [cited 2012 December 20th]; Available from: http://www.monitor.co.ug/News/Education/-/688336/759052/-/view/ printVersion/-/13hs21sz/-/index.html
51. Fake antimalaria drugs in Cambodia. Rozendaal J, Lancet 2001 357 9259 890 890
52. Bagozzi D, Substandard and counterfeit medicines WHO 2003 Fact sheet 275. Available from: http://www.who.int/mediacentre/factsheets/2003/fs275/en/
53. Identification of the 'wrong' active pharmaceutical ingredient in a counterfeit Halfan™ drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry. Wolff J-C, Thomson LA, Eckers C, Rapid Commun Mass Spectrom 2003 17 3 215 221 10.1002/rcm.893 12539187
54. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) ICH 2013 [cited 2013 August 20th]; Available from: http://www.ich.org/
55. WHO, Prequalification Programme. A United Nations Programme managed by WHO 2013 [cited 2013 February 8th]; Available from: http://apps.who.int/prequal/
56. Global threat of counterfeit drugs: Why industry and governments must communicate the dangers. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ, PLoS Med 2005 2 4 0302 0308
57. Editorial, Fighting fake drugs: the role of WHO and pharma. The Lancet Editorial, Lancet 2011 377 1 10.1016/S0140-6736(10)62319-7 21195234
58. Counterfeit and Substandard Anti-infectives in Developing Countries. Newton PN, Fernández FM, Green MD, Primo-Carpenter J, White NJ, Antimicrob Resist Dev Ctries 2009 Chapter 24 413 443
59. Epidemic of Plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003. Leslie T, Kaur H, Mohammed N, Kolaczinski K, Ord RL, Rowland M, Emerg Infect Dis 2009 15 11 1753 1759 10.3201/eid1511.090886 19891862
60. Sabartova J, Toumi A, World Health Organization, Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa WHO 2011 118 Available from: http://www.who.int/entity/medicines/ publications/WHO-QAMSA-report.pdf
61. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Nayyar GML, Breman JG, Newton PN, Herrington J, Lancet Infect Dis 2012 12 6 488 496 10.1016/S1473-3099(12)70064-6 22632187
62. Arrow KJ, Panosian CB, Gelband H, Saving lives, buying time: economics of malaria drugs in an age of resistance Washington D.C: The National Academies Press, Committee on the Economics of Antimalarial Drugs Board on Global Health. Institute of Medicine of the National Academies, 2004
63. Murder by fake drugs: Time for international action. Newton PN, White NJ, Rozendaal JA, Green MD, Br Med J 2002 324 7341 800 801 10.1136/bmj.324.7341.800
64. Report of the Open-ended Working Group to Identify the Actions, Activities and Behaviours that Result in Substandard/Spurious/Falsely-labelled/ Falsified/Counterfeit Medical Products. WHO, Second Meeting of the Member State Mechanism on Substandard,Spurious,Falsely-labelled,Falsified,Counterfeit Medical Products. Provisional Agenda item. Vol. A/MSM/2/3 2013 World Health Organization Available from: http://apps.who.int/gb/ssffc/pdf-files/A-MSM2-3-en. pdf
65. Open-ended working group to identify the actions, activities and behaviours that result in substandard/spurious/falsely-labelled/falsified/ counterfeit medical products. WHO, Provisional agenda item 3. Report by the Secretariat. Vol. A/MSM/WG/1/2 World Health Organization 2013 Available from: http://apps.who.int/gb/ssffc/pdf-files/WG1b/A-MSM-WG1-2-en.pdf
66. WHO, Substandard/Spurious/Falsely-labelled/Falsified/Counterfeit medical products. Situation report by the Secretariat. WHO, First Meeting of the Member State Mechanism on Substandard/Spurious/Falsely-labelled/Falsified/Counterfeit Medical Products. Provisional Agenda item 4 World Health Organization 2012 Available from: http://apps.who.int/gb/ssffc/pdf-files/A-MSM1-INF1-en.pdf
67. Options for the structure and governance of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products. WHO, First meeting of the Member State Mechanism on Substandard,Spurious, Falsely-labelled,Falsified,Counterfeit medical products. Provisional Agenda item 6 World Health Organization 2012 Available from: http://apps.who.int/gb/ssffc/ pdf-files/A-MSM1-3-en.pdf
68. WHO, Substandard/spurious/falsely-labelled/falsified/counterfeit medical products. Report by the Secretariat in Sixty-sixth World Health Assembly. Provisional agenda item 17.1 World Health Organization 2013 Available from: http://apps.who.int/gb/ebwha/pdf-files/WHA66/A66-22-en.pdf
69. WHO project for the surveillance and monitoring of SSFFC medical products. WHO, WHO Drug Information. Quality and Safety of Medicines 2013 115
70. World Health Organization, WHO List of Prequalified Quality Control Laboratories Version 26th Edition 2013 [cited 2013 August 20th]; Available from: http://www.who.int/prequal/lists/pq-qc labs list.pdf
71. WHO, World Malaria Report 2011 World Health Organization 2011 [cited 2013 March, 17th] Available from: http://www.who.int/malaria/world-malaria-report- 2011/9789241564403-eng.pdf